{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:58:11Z","timestamp":1774547891649,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ekir.2020.12.012","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T23:24:14Z","timestamp":1608333854000},"page":"594-604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis\u2014A Randomized Clinical Trial"],"prefix":"10.1016","volume":"6","author":[{"given":"Markus","family":"Ketteler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Wiecek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R.","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Rekowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhard","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Karus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2020.12.012_bib1","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.012_bib4","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.012_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2020.12.012_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1744-9987.2007.00540.x","article-title":"Patient Registration Committee of the Japanese Society for Dialysis Therapy, Tokyo, Japan. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan","volume":"12","author":"Nakai","year":"2008","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.ekir.2020.12.012_bib7","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2215\/CJN.00810110","article-title":"Serum phosphate and mortality in patients with chronic kidney disease","volume":"5","author":"Eddington","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074996","article-title":"Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study","volume":"8","author":"McGovern","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2020.12.012_bib9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","article-title":"Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study","volume":"30","author":"Fern\u00e1ndez-Mart\u00edn","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.012_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cca.2017.09.005","article-title":"Phosphorus and mortality risk in end-stage renal disease: A meta-analysis","volume":"474","author":"Hou","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ekir.2020.12.012_bib11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","article-title":"Arterial calcification in chronic kidney disease: key roles for calcium and phosphate","volume":"109","author":"Shanahan","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2020.12.012_bib12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/ki.2013.185","article-title":"Use of phosphate-binding agents is associated with a lower risk of mortality","volume":"84","author":"Cannata-Andia","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.012_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2020.12.012_bib14","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/ndt\/gfs418","article-title":"COSMOS: the dialysis scenario of CKD-MBD in Europe","volume":"27","author":"Fern\u00e1ndez-Mart\u00edn","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.012_bib16","first-page":"4","article-title":"Phosphate binders and nonphosphate effects in the gastrointestinal tract","volume":"30","author":"Biruete","year":"2020","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2020.12.012_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/cs0560407","article-title":"Absorption of inorganic phosphate in the human small intestine","volume":"56","author":"Walton","year":"1979","journal-title":"Clin Sci"},{"key":"10.1016\/j.ekir.2020.12.012_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00424-018-2221-1","article-title":"The role of SLC34A2 in intestinal phosphate absorption and phosphate homeostasis","volume":"471","author":"Marks","year":"2019","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.ekir.2020.12.012_bib19","doi-asserted-by":"crossref","first-page":"G233","DOI":"10.1152\/ajpgi.00032.2019","article-title":"Paracellular transport of phosphate along the intestine","volume":"317","author":"Kn\u00f6pfel","year":"2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ekir.2020.12.012_bib20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41581-019-0159-y","article-title":"Mechanisms of phosphate transport","volume":"15","author":"Levi","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib21","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1681\/ASN.2009050559","article-title":"Intestinal npt2b plays a major role in phosphate absorption and homeostasis","volume":"20","author":"Sabbagh","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.ackd.2010.11.004","article-title":"Intestinal phosphate transport","volume":"18","author":"Sabbagh","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4 Pt 1","key":"10.1016\/j.ekir.2020.12.012_bib23","first-page":"G756","article-title":"Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake","volume":"277","author":"Hattenhauer","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ekir.2020.12.012_bib24","doi-asserted-by":"crossref","first-page":"F1466","DOI":"10.1152\/ajprenal.00279.2009","article-title":"Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate","volume":"297","author":"Giral","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2020.12.012_bib25","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2011121213","article-title":"Npt2b deletion attenuates hyperphosphatemia associated with CKD","volume":"23","author":"Schiavi","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00424-018-2111-6","article-title":"Effect of variations in dietary Pi intake on intestinal Pi transporters (NaPi-IIb, PiT-1, and PiT-2) and phosphate-regulating factors (PTH, FGF-23, and MEPE)","volume":"470","author":"Aniteli","year":"2018","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.ekir.2020.12.012_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00424-018-2246-5","article-title":"Clinical aspects of the phosphate transporters NaPi-IIa and NaPi-IIb: mutations and disease associations","volume":"471","author":"Lederer","year":"2019","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.ekir.2020.12.012_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ndt\/gfy410","article-title":"Magnesium but not nicotinamide prevents vascular calcification in experimental uraemia","volume":"35","author":"Kaesler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.ekir.2020.12.012_bib29","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1681\/ASN.2015020117","article-title":"Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD","volume":"26","author":"Isakova","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/ndt\/14.5.1195","article-title":"Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine","volume":"14","author":"Katai","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.012_bib31","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/ndt\/gfh781","article-title":"Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure","volume":"20","author":"Eto","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.012_bib32","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1681\/ASN.2018101058","article-title":"Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: The COMBINE Trial","volume":"30","author":"Ix","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib33","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib34","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/089686080902900515","article-title":"The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients","volume":"29","author":"Young","year":"2009","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.ekir.2020.12.012_bib35","first-page":"58","article-title":"Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial","volume":"31","author":"Shahbazian","year":"2011","journal-title":"Nefrologia"},{"key":"10.1016\/j.ekir.2020.12.012_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0167-8140(93)90133-S","article-title":"Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy","volume":"27","author":"Horsman","year":"1993","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ekir.2020.12.012_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/02841869609098504","article-title":"Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy","volume":"35","author":"Stratford","year":"1996","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ekir.2020.12.012_bib38","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1046\/j.1523-1755.63.s84.36.x","article-title":"N-Methyl-2-pyridone-5-carboxamide: a novel uremic toxin?","author":"Rutkowski","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2020.12.012_bib39","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1681\/ASN.2012030240","article-title":"Nanoparticle-based test measures overall propensity for calcification in serum","volume":"23","author":"Pasch","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2215\/CJN.04720416","article-title":"Blood calcification propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE Trial","volume":"12","author":"Pasch","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1681\/ASN.2013060635","article-title":"Serum calcification propensity predicts all-cause mortality in predialysis CKD","volume":"25","author":"Smith","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib42","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pst.1536","article-title":"A\u00a0structured approach to choosing estimands and estimators in longitudinal clinical trials","volume":"11","author":"Mallinckrodt","year":"2012","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ekir.2020.12.012_bib43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00467-015-3208-1","article-title":"Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis","volume":"31","author":"El Borolossy","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2020.12.012_bib44","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A\u00a0phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.012_bib45","doi-asserted-by":"crossref","first-page":"c8","DOI":"10.1159\/000084653","article-title":"Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate","volume":"100","author":"Hutchison","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2020.12.012_bib46","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1681\/ASN.2018080832","article-title":"Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial","volume":"30","author":"Block","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1016\/j.ekir.2020.12.012_bib47","article-title":"Validation of a serum calcification propensity test for the prediction of all-cause mortality among dialysis patients","volume":"35","author":"Ramos Sanchez","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.012_bib48","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ndt\/gfw042","article-title":"Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study","volume":"32","author":"Lenglet","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.12.012_bib49","first-page":"1","article-title":"The effect of coadminstration of nicotinamide and calcium-based phosphate binder on hyperphophatemia in patients undergoing hemodialysis","volume":"5","author":"Allam","year":"2012","journal-title":"Adv Nat Sci"},{"key":"10.1016\/j.ekir.2020.12.012_bib50","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.ki.5000381","article-title":"Diarrhea induced by high doses of nicotinamide in dialysis patients","volume":"69","author":"Delanaye","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.012_bib51","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1523-1755.2004.00482.x","article-title":"Nicotinamide suppresses hyperphosphatemia in hemodialysis patients","volume":"65","author":"Takahashi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.012_bib52","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1111\/j.1523-1755.2005.00583_8.x","article-title":"Thrombocytopenia induced by nicotinamide in hemodialysis patients","volume":"68","author":"Rottembourg","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.12.012_bib53","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/toxins8110339","article-title":"N-Methyl-2-pyridone-5-carboxamide (2PY)\u2014major metabolite of nicotinamide: an update on an old uremic toxin","volume":"8","author":"Lenglet","year":"2016","journal-title":"Toxins (Basel)"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492031843X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492031843X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:35:54Z","timestamp":1762832154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802492031843X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S246802492031843X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2020.12.012","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis\u2014A Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2020.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}